Clinical Trials Logo

Esophagitis, Peptic clinical trials

View clinical trials related to Esophagitis, Peptic.

Filter by:

NCT ID: NCT04531475 Recruiting - Reflux Esophagitis Clinical Trials

Study to Evaluate the Safety and Efficacy of X842 in Patients With Reflux Esophagitis

Start date: January 22, 2019
Phase: Phase 2
Study type: Interventional

The purpose of the study is to investigate the efficacy and dose-effect relationship of X842 capsules at different dosages in the treatment of reflux esophagitis for 4 weeks in comparison with lansoprazole enteric-coated capsules.

NCT ID: NCT04501627 Completed - Esophagitis Peptic Clinical Trials

A Study on Vonoprazan in the Real-world Clinical Practice in China

VIEW
Start date: December 24, 2020
Phase:
Study type: Observational

The purpose of this study is to evaluate the safety of Vonoprazan by assessing all adverse events (AEs), serious adverse events (SAEs), and adverse drug reactions (ADRs) in routine clinical settings in China.

NCT ID: NCT04491734 Completed - Clinical trials for Gastroesophageal Reflux

Tolerability Study of a Novel Microbiome Therapeutic in Subjects With Gastroesophageal Reflux Disease

Start date: June 1, 2020
Phase: N/A
Study type: Interventional

This is a remote study. No office visits required. The purpose and efficacy endpoint of this study is to assess whether GERD patients tolerate ISOT-101. In addition, usage of the ReQuest validated questionnaire to measure GERD symptoms will be explored as well as usage of the validated SF-36 quality of life (QoL) questionnaire. Each subject serves as his/her own control. Relative tolerability in subjects both on and off proton pump inhibitors (PPIs) will be compared. Subjects naive to PPIs, currently taking PPIs and historically on PPIs will be evaluated with ReQuest and QoL scores. In addition, survey measurements will be taken on a subset of 10 subjects that are non-responders to PPIs. These will not be included in the statistical analysis with the above groups. A tertiary endpoint of this study is to assess any relevant adverse events that occur.

NCT ID: NCT04411823 Recruiting - Clinical trials for Gastroesophageal Reflux

Post-sleeve Gastrectomy Gastroesophageal Reflux Disease Prediction

Start date: February 1, 2021
Phase: N/A
Study type: Interventional

Researchers are trying to identify predictors for gastroesophageal reflux disease after sleeve gastrectomy.

NCT ID: NCT04400136 Not yet recruiting - Clinical trials for Bariatric Surgery Candidate

PPI Therapy Impact on GERD After Sleeve Gastrectomy

Start date: July 1, 2020
Phase: Early Phase 1
Study type: Interventional

The trial would to try to establish: - The best post-operative PPI prescription protocol after Sleeve Gastrectomy - The impact of PPI therapy on postoperative peptic diseases (erosive gastropathies, ulcers, duodenitis, esophagitis and/or Barrett) - The impact of PPI therapy on post-operative GERD symptoms (assessed with the use of two standard tests: MRGE-HRQL and GERDQ

NCT ID: NCT04360252 Recruiting - Clinical trials for Gastroesophageal Reflux

Gracie Diet for Gastroesophageal Reflux Disease

Start date: November 13, 2020
Phase: N/A
Study type: Interventional

GERD, is a common and chronic world-wide disease. Cardinal symptoms of this condition are heartburn-regurgitation, and sometimes with extra-intestinal symptoms that can affect patients' quality of life. Proton pump inhibitors (PPIs) potently inhibit gastric acid secretion and are widely used for treatment of acid-related diseases. This class of medications is the most widely used for the management of GERD. H2 Receptor Antagonists (H2RAs) are another type of medication used to of uncomplicated GERD, gastric or duodenal ulcers, gastric hypersecretion, and for mild to infrequent heartburn or indigestion. H2RAs decrease gastric acid secretion by reversibly binding to histamine H2 receptors located on gastric parietal cells, thereby inhibiting the binding and action of the endogenous ligand histamine. Dietary modification is endorsed by the National Institutes of Health and the American College of Gastroenterology as a first-line therapy for patients with GERD. The Gracie Diet is thought to play an important role in the prevention of GERD. The concept behind this diet is that the consumption of proper food combinations promotes optimal health by preventing unhealthy chemical reactions in the digestive process such as fermentation and acidity. This diet describes the benefits of combining different foods together and the downsides of combining others. It provides guidance on avoiding specific foods and combinations of foods that may aggravate GERD, and adopting meal spacing habits to improve overall health outcomes. The idea is that such dietary changes support more efficient digestion and encourage healthier lifestyles (i.e. smoking cessation, elimination of alcohol intake, avoidance of soda consumption and desserts). This diet also supports the acquisition of healthy eating habits characterized by higher consumption of fruits, vegetables, and whole grains, and encourages a reduction in the intake of saturated fat, sodium, added sugars, and canned foods. Limiting beverage consumption of water or fresh coconut water between meals is also encouraged. In this pilot study, the investigators hypothesized that the Gracie diet it could be an alternative option to improve GERD symptoms in those patients who do not respond to standard doses of PPI and/or H2 receptor antagonists.

NCT ID: NCT04311541 Withdrawn - Clinical trials for Gastroesophageal Reflux Disease

A Study of Dexlansoprazole Modified Release (MR) in Gastroesophageal Reflux Disease (GERD) Participants in the Russian Federation

INTEGRO
Start date: March 15, 2020
Phase:
Study type: Observational

The primary purpose of the study is to evaluate effect of Dexilant treatment among GERD participants in the Russian Federation.

NCT ID: NCT04255693 Recruiting - Clinical trials for Gastroesophageal Reflux Disease

Real-life Study of Changes of Gastroesophageal Reflux Disease Manifestations Due to Behavioural and Diet Adherence

Start date: January 31, 2020
Phase: N/A
Study type: Interventional

This study is aimed to investigate the role of long-term diet adherence on manifestations of gastroesophageal reflux disease

NCT ID: NCT04248296 Completed - Clinical trials for Gastroesophageal Reflux Disease With Esophagitis

Evaluate the Intestinal Microbiome in Patients With Erosive Gastroesophageal Reflux Disease and in Asymptomatic Healthy Controls

Start date: May 10, 2017
Phase:
Study type: Observational

. In this study, we investigated intestinal microbiomes, in individuals with Gastroesophageal Reflux Disease and healthy individuals, using metagenomic techniques.

NCT ID: NCT04237857 Recruiting - Clinical trials for Gastroesophageal Reflux

Long Term Incidence and Effect of de Novo GERD After Laparoscopic Sleeve Gastrectomy in Chinese Population

Start date: February 1, 2020
Phase:
Study type: Observational

To evaluate the long-term incidence and effects of gastroesophageal reflux disease in the Chinese population after laparoscopic sleeve gastrectomy.